BBNX
Beta Bionics, Inc. Common StockBBNX
BBNX
About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Employees: 354
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
97.61% more ownership
Funds ownership: 0% [Q4 2024] → 97.61% (+97.61%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
16%
downside
Avg. target
$22
15%
upside
High target
$30
57%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Lake Street Frank Takkinen | 57%upside $30 | Buy Assumed | 12 Jun 2025 |
Goldman Sachs David Roman | 16%downside $16 | Neutral Initiated | 30 May 2025 |
Wolfe Research Mike Polark | 5%upside $20 | Outperform Initiated | 30 May 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber - Head, IR Sean Saint - President and Chief Executive Officer Stephen Feider - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Mike Kratky - Leerink Partners Matthew Blackman - Stifel Travis Steed - Bank of America Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Kelly Close - Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
1 month ago
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Beta Bionics to Present at the Bank of America Securities Health Care Conference
IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time).
Negative
Seeking Alpha
1 month ago
Beta Bionics: Slowing Down Or Being Conservative?
Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.
Neutral
GlobeNewsWire
2 months ago
Beta Bionics to Host Investor Event on June 22, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time).
Neutral
GlobeNewsWire
2 months ago
Beta Bionics Announces Board Appointment of Gerard Michel
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company.
Neutral
GlobeNewsWire
2 months ago
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025.
Neutral
GlobeNewsWire
3 months ago
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance.
Positive
24/7 Wall Street
4 months ago
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
Positive
Seeking Alpha
4 months ago
Beta Bionics: A Sugar Rush For This IPO
Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years.
Charts implemented using Lightweight Charts™